Clinical trial

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

NCT03387553

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-06-06

PhaseEARLY_PHASE1

Study timeline

Study start (actual)2018-06-06Date precision: day

Registry last updated2026-09-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Breast Cancer Femaleunresolved

Breast Cancer, Maleunresolved

Invasive Breast Cancerunresolved

HER2-positive Breast Cancerunresolved

HER2 Positive Breast Carcinomaunresolved

Stage II Breast Cancerunresolved

Stage III Breast Cancerunresolved

Interventions

Dendritic Cell Vaccine (DC1)BIOLOGICAL

Neoadjuvant ChemotherapyDRUG

Curative SurgeryPROCEDURE

Sponsors & collaborators

H. Lee Moffitt Cancer Center and Research Institutelead sponsor

United States Department of Defensecollaborator

Mapped research locations

TampaFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03387553 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.